Citations

Clear

9383 citation(s) found for "Thomas, PS".

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Micallef, Ivana N. , Maurer, Matthew J. , Wiseman, Gregory A., Nikcevich, Daniel A., Kurtin, Paul J. , Cannon, Michael W., Pérez, Domingo G., Soori, Gamini S. , Link, Brian K. , Habermann, Thomas M. , Witzig, Thomas E. , Maurer, Matthew , Link, Brian K

Mayo Clinic

Blood | June 15, 2011 | Volume: 118 | Issue: 15 | Pages: 4053-4061

10.1182/blood-2011-02-336990 | PMID 21673350 Get It

AbstractApproximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase 2 trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in untreated DLBCL. A secondary aim was to assess the efficacy of interim positron emission tomography (PET) to predict outcome in DLBCL. Standard R-CHOP with the addition of E 360 mg/m2 intravenously was administered for 6 cycles. A total of 107 patients were enrolled in the study. Toxicity was similar to standard R-CHOP. Overall response rate in the 81 eligible patients was 96% (74% CR/CRu) by computed tomography scan and 88% by PET. By intention to treat analysis, at a median follow-up of 43 months, the event-free survival (EFS) and overall survival (OS) at 3 years in all 107 patients were 70% and 80%, respectively. Interim PET was not associated with EFS or OS. Comparison with a cohort of 215 patients who were treated with R-CHOP showed an improved EFS in the ER-CHOP patients. ER-CHOP is well tolerated and results appear promising as a combination therapy. This study was registered at www.clinicaltrials.gov as #NCT00301821.
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation
Ding, Husheng, Hackbarth, Jennifer S., Schneider, Paula A., Peterson, Kevin L. , Meng, X. Wei, Dai, Haiming , Witzig, Thomas E. , Kaufmann, Scott H. , Dai, Haiming

Mayo Clinic

Blood | June 15, 2011 | Volume: 118 | Issue: 18 | Pages: 4872-4881

10.1182/blood-2011-02-334870 | PMID 21673341 Get It

Abstract The mechanism of cytotoxicity of farnesyltransferase inhibitors is incompletely understood and seems to vary depending on the cell type. To identify potential determinants of sensitivity or resistance for study in the accompanying clinical trial (Witzig et al, page 4882), we examined the mechanism of cytotoxicity of tipifarnib in human lymphoid cell lines. Based on initial experiments showing that Jurkat variants lacking Fas-associated death domain or procaspase-8 undergo tipifarnib-induced apoptosis, whereas cells lacking caspase-9 or overexpressing Bcl-2 do not, we examined changes in Bcl-2 family members. Tipifarnib caused dose-dependent up-regulation of Bim in lymphoid cell lines (Jurkat, Molt3, H9, DoHH2, and RL) that undergo tipifarnib-induced apoptosis but not in lines (SKW6.4 and Hs445) that resist tipifarnib-induced apoptosis. Further analysis demonstrated that increased Bim levels reflect inhibition of signaling from c-Raf to MEK1/2 and ERK1/2. Additional experiments showed that down-regulation of the Ras guanine nucleotide exchange factor RasGRP1 diminished tipifarnib sensitivity, suggesting that H-Ras or N-Ras is a critical farnesylation target upstream of c-Raf in lymphoid cells. These results not only trace a pathway through c-Raf to Bim that contributes to tipifarnib cytotoxicity in human lymphoid cells but also identify potential determinants of sensitivity to this agent.
APOE genotype and cognitive decline in a middle-aged cohort
Blair, Cindy K. , Folsom, Aaron R. , Bray, Molly S., Boerwinkle, Eric , Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

Neurology | June 14, 2011 | Volume: 64 | Issue: 2 | Pages: 268-276

10.1212/01.wnl.0000149643.91367.8a | PMID 15668424 Get It

Retrograde Supra-Aortic Stent Placement Combined With Open Carotid or Subclavian Artery Revascularization
Garg, Nitin , Duncan, Audra A. , Agarwal, Gautam , Kalra, Manju, Gloviczki, Péter , Bower, Thomas C., Oderich, Gustavo S. , Gloviczki, Péter

Mayo Clinic

Vascular and Endovascular Surgery | June 13, 2011 | Volume: 45 | Issue: 6 | Pages: 527-535

10.1177/1538574411408743 | PMID 21669861 Get It

Purpose: To review the outcomes of retrograde supra-aortic vessel stent (RSAS) placement combined with open carotid or subclavian artery revascularization. Methods: Retrospective review of all consecutive patients between 1995 and 2010, excluding transfemoral procedures or isolated retrograde stent placement. Results: There were 11 patients (9 females, mean age 65 years). Open revascularization included carotid endarterectomy in 6 patients, carotid-subclavian bypass in 3, and carotid-carotid bypass in 2 patients. There were no operative deaths or neurological events. All symptomatic patients improved. Over a mean follow-up of 24 months, One patient developed common carotid artery (CCA) in-stent dissection and symptomatic restenosis treated with subclavian-carotid bypass. Another 3 patients had asymptomatic restenosis of the carotid bifurcation but required no intervention. Conclusions: Retrograde stenting of the common carotid or innominate artery is a safe and effective method to provide inflow in selected patients with severe supra-aortic vessel disease who require concomitant open carotid or subclavian artery reconstructions.
Update in Intracerebral Hemorrhage
Aguilar, Maria I. , Brott, Thomas G.

Mayo Clinic

The Neurohospitalist | June 13, 2011 | Volume: 1 | Issue: 3 | Pages: 148-159

10.1177/1941875211409050 | PMID 23983850 Get It

Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is defined as bleeding within the brain parenchyma. Intracranial hemorrhage includes bleeding within the cranial vault and encompasses ICH, subdural hematoma, epidural bleeds, and subarachnoid hemorrhage (SAH). This review will focus only on ICH. This stroke subtype accounts for about 10% of all strokes. The hematoma locations are deep or ganglionic, lobar, cerebellar, and brain stem in descending order of frequency. Intracerebral hemorrhage occurs twice as common as SAH and is equally as deadly. Risk factors for ICH include hypertension, cerebral amyloid angiopathy, advanced age, antithrombotic therapy and history of cerebrovascular disease. The clinical presentation is “stroke like” with sudden onset of focal neurological deficits. Noncontrast head computerized tomography (CT) scan is the standard diagnostic tool. However, newer neuroimaging techniques have improved the diagnostic yield in terms of underlying pathophysiology and may aid in prognosis. Intracerebral hemorrhage is a neurological emergency. Medical care begins with stabilization of airway, breathing function, and circulation (ABCs), followed by specific measures aimed to decrease secondary neurological damage and to prevent both medical and neurological complications. Reversal of coagulopathy when present is of the essence. Blood pressure management can be key and continues as an area of debate and ongoing research. Surgical evacuation of ICH is of unproven benefit though a subset of well-selected patients may have improved outcomes. Ventriculostomy and intracranial pressure (ICP) monitoring are interventions also used in this patient population. To date, hemostatic medications and neuroprotectants have failed to result in clinical improvement. A multidisciplinary approach is recommended, with participation of vascular neurology, vascular neurosurgery, critical care, and rehabilitation medicine as the main players.
Precision across the Analytical Measuring Range of a Quantitative Real-Time PCR Assay for Cytomegalovirus Detection among Three Clinical Laboratories
Grys, Thomas E. , Duquette, Doreen L., White, Bruce A., Irish, Cole L., Hata, D. Jane , Pritt, Bobbi S. , Pritt, Bobbi S , Grys, Thomas E

Mayo Clinic

Journal of Clinical Microbiology | June 9, 2011 | Volume: 49 | Issue: 8 | Pages: 3044-3046

10.1128/jcm.00486-11 | PMID 21653778 Get It

ABSTRACT This study measured the precision of a quantitative laboratory-developed real-time PCR test for cytomegalovirus performed at three different clinical laboratories that use the same methodology. The overall standard deviation (adjusted for analyte level) was 0.18 log 10 copies/ml, and there was no significant relationship between standard deviation and analytical measuring range.
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials
Blanke, Charles D. , Bot, Brian M. , Thomas, David M. , Köhne, Claus-Henning, Seymour, Michel , Gramont, Aimery de , Goldberg, Richard M. , Sargent, Daniel J. , Bleyer, Archie , Köhne, C.-H., Sargent, Daniel J , Seymour, Matthew T

Mayo Clinic

Journal of Clinical Oncology | June 7, 2011 | Volume: 29 | Issue: 20 | Pages: 2781-2786

10.1200/jco.2010.33.5281 | PMID 21646604 Get It

PurposeColorectal cancer predominantly occurs in the elderly, but approximately 5% of patients are 50 years old or younger. We sought to determine whether young age is prognostic, or whether it influences efficacy/toxicity of chemotherapy, in patients with advanced disease.MethodsWe analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy. End points included progression-free survival (PFS), overall survival (OS), response rate (RR), and grade 3 or worse adverse events. Stratified Cox and adjusted logistic-regression models were used to test for age effects and age-treatment interactions.ResultsA total of 793 patients (13%) were younger than 50 years old; 188 of these patients (3% of total patients) were younger than 40 years old. Grade 3 or worse nausea (10% v 7%; P = .01) was more common, and severe diarrhea (11% v 14%; P = .001) and neutropenia (23% v 26%; P < .001) were less common in young (younger than 50 years) than in older (older than 50 years) patients. Age was prognostic for PFS, with poorer outcomes occurring in those younger than 50 years (median, 6.0 v 7.5 months; hazard ratio, 1.10; P = .02), but it did not affect RR or OS. In the subset of monotherapy versus combination chemotherapy trials, the relative benefits of multiagent chemotherapy were similar for young and older patients. Results were comparable when utilizing an age cut point of 40 years.ConclusionYoung age is modestly associated with poorer PFS but not OS or RR in treated patients with aCRC, and young patients have more nausea but less diarrhea and neutropenia with chemotherapy in general. Young versus older patients derive the same benefits from combination chemotherapy. Absent results of a clinical trial, standard combination chemotherapy approaches are appropriate for young patients with aCRC.
Inherited Variants in Mitochondrial Biogenesis Genes May Influence Epithelial Ovarian Cancer Risk
Permuth‐Wey, Jennifer, Chen, Y. Ann , Tsai, Ya-Yu, Chen, Zhihua , Qu, Xiaotao , Lancaster, Johnathan M., Stockwell, Heather, Dagne, Getachew , Iversen, Edwin S., Barnholtz‐Sloan, Jill S. , Cunningham, Julie M. , Vierkant, Robert A. , Sutphen, Rebecca , McLaughlin, John, Narod, Steven A., Goode, Ellen L. , Schildkraut, Joellen M. , Fenstermacher, David, Phelan, Catherine M., Sellers, Thomas A. , Risch, Harvey A. , Fridley, Brooke L. , McLaughlin, John, Vierkant, Robert A , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 7, 2011 | Volume: 20 | Issue: 6 | Pages: 1131-1145

10.1158/1055-9965.epi-10-1224 | PMID 21447778 Get It

Abstract Background: Mitochondria contribute to oxidative stress, a phenomenon implicated in ovarian carcinogenesis. We hypothesized that inherited variants in mitochondrial-related genes influence epithelial ovarian cancer (EOC) susceptibility. Methods: Through a multicenter study of 1,815 Caucasian EOC cases and 1,900 controls, we investigated associations between EOC risk and 128 single nucleotide polymorphisms (SNPs) from 22 genes/regions within the mitochondrial genome (mtDNA) and 2,839 nuclear-encoded SNPs localized to 138 genes involved in mitochondrial biogenesis (BIO, n = 35), steroid hormone metabolism (HOR, n = 13), and oxidative phosphorylation (OXP, n = 90) pathways. Unconditional logistic regression was used to estimate OR and 95% CI between genotype and case status. Overall significance of each gene and pathway was evaluated by using Fisher's method to combine SNP-level evidence. At the SNP level, we investigated whether lifetime ovulation, hormone replacement therapy (HRT), and cigarette smoking were confounders or modifiers of associations. Results: Interindividual variation involving BIO was most strongly associated with EOC risk (empirical P = 0.050), especially for NRF1, MTERF, PPARGC1A, ESRRA, and CAMK2D. Several SNP-level associations strengthened after adjustment for nongenetic factors, particularly for MTERF. Statistical interactions with cigarette smoking and HRT use were observed with MTERF and CAMK2D SNPs, respectively. Overall variation within mtDNA, HOR, and OXP was not statistically significant (empirical P &gt; 0.10). Conclusion: We provide novel evidence to suggest that variants in mitochondrial biogenesis genes may influence EOC susceptibility. Impact: A deeper understanding of the complex mechanisms implicated in mitochondrial biogenesis and oxidative stress may aid in developing strategies to reduce morbidity and mortality from EOC. Cancer Epidemiol Biomarkers Prev; 20(6); 1131–45. ©2011 AACR.
Carotid Endarterectomy is Superior to Carotid Angioplasty and Stenting for Perioperative and Long-Term Results
Pipinos, Iraklis I. , Garg, Nitin , Johanning, Jason M. , Lynch, Thomas G. , Longo, G. Matthew, Arya, Shipra

Mayo Clinic

Vascular and Endovascular Surgery | June 6, 2011 | Volume: 45 | Issue: 6 | Pages: 490-498

10.1177/1538574411407083 | PMID 21646236 Get It

Objective: Carotid angioplasty and stenting (CAS) has challenged carotid endarterectomy (CEA) as the therapy of choice for carotid disease. This meta-analysis aims at summarizing the most current body of evidence. Methods: All prospective, controlled clinical trials comparing CEA versus CAS were included. The outcome measures of interest were relative risk (RR) of 30-day stroke, 30-day stroke/death, long-term risk of stroke, and risk of restenosis. Results: The RR of 30-day stroke for CAS was 1.6 times that of CEA (RR 1.6; 95%CI 1.2-2.0, P = .001). The 30-day RR of stroke/death was 1.5 times higher for CAS (RR 1.5; 95%CI 1.1-2.1, P = .008). There was a higher risk of long-term stroke (RR 1.2; 95%CI 1.0-1.5, P = .043). The risk of restenosis was twice for CAS (RR 1.8; 95%CI 1.1-3.1, P = .04). Conclusion: The 30-day RR of stroke, stroke/death, long-term risk of stroke, and risk of restenosis are consistently higher for carotid artery stenting (CAS).
Myocardial Infarction After Carotid Stenting and Endarterectomy
Blackshear, Joseph L., Cutlip, Donald E. , Roubin, Gary S., Hill, Michael D. , Leimgruber, Pierre P., Begg, Richard J., Eidt, John F. , Narins, Craig R. , Prineas, Ronald J. , Glasser, Stephen P. , Voeks, Jenifer H. , Brott, Thomas G. , Investigators, for the CREST, Cohen, David Jonathan , Investigators, for the CREST, Hill, Michael D

Mayo Clinic

Circulation | May 24, 2011 | Volume: 123 | Issue: 22 | Pages: 2571-2578

10.1161/circulationaha.110.008250 | PMID 21606394 Get It

Background— The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) found a higher risk of stroke after carotid artery stenting and a higher risk of myocardial infarction (MI) after carotid endarterectomy. Methods and Results— Cardiac biomarkers and ECGs were performed before and 6 to 8 hours after either procedure and if there was clinical evidence of ischemia. In CREST, MI was defined as biomarker elevation plus either chest pain or ECG evidence of ischemia. An additional category of biomarker elevation with neither chest pain nor ECG abnormality was prespecified (biomarker+ only). Crude mortality and risk-adjusted mortality for MI and biomarker+ only were assessed during follow-up. Among 2502 patients, 14 MIs occurred in carotid artery stenting and 28 MIs in carotid endarterectomy (hazard ratio, 0.50; 95% confidence interval, 0.26 to 0.94; P =0.032) with a median biomarker ratio of 40 times the upper limit of normal. An additional 8 carotid artery stenting and 12 carotid endarterectomy patients had biomarker+ only (hazard ratio, 0.66; 95% confidence interval, 0.27 to 1.61; P =0.36), and their median biomarker ratio was 14 times the upper limit of normal. Compared with patients without biomarker elevation, mortality was higher over 4 years for those with MI (hazard ratio, 3.40; 95% confidence interval, 1.67 to 6.92) or biomarker+ only (hazard ratio, 3.57; 95% confidence interval, 1.46 to 8.68). After adjustment for baseline risk factors, both MI and biomarker+ only remained independently associated with increased mortality. Conclusions— In patients randomized to carotid endarterectomy versus carotid artery stenting, both MI and biomarker+ only were more common with carotid endarterectomy. Although the levels of biomarker elevation were modest, both events were independently associated with increased future mortality and remain an important consideration in choosing the mode of carotid revascularization or medical therapy. Clinical Trial Registration— URL: http://www.ClinicalTrials.gov . Unique identifier: NCT00004732.